[Federal Register Volume 66, Number 156 (Monday, August 13, 2001)]
[Notices]
[Pages 42553-42554]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-20194]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Melanoma Antigens and 
Their Use in Diagnostic and Therapeutic Methods

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive license to practice the inventions embodied in U.S. Patent 
Applications S/N 08/231,565, filed on April 22, 1994, and now U.S. 
Patent 5,874,560, which issued on February 23, 1999; S/N 08/417,174, 
filed on April 5, 1995, and now U.S. Patent 5,844,075; S/N 09/007,961, 
filed on January 16, 1998, and now U.S. Patent 5,994,523, issued 
November 30, 1999; S/N 09/073,138, filed on May 5, 1998; and S/N 09/
267,439, filed on March 12, 1999, all entitled ``Melanoma Antigens and 
Their Use in Diagnostic and Therapeutic Methods'', to BioVex Limited, 
of the United Kingdom. The patent rights in these inventions have

[[Page 42554]]

been assigned to the United States of America.
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to herpesvirus vectors encoding MART-1 
and/or gp100 for use as immunotherapeutic vaccines against melanoma in 
humans, and specifically excluding the use of MART-1 and/or gp100 in 
any other manner or form.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before October 12, 
2001 will be considered.

ADDRESSES: Requests for copies of the patent/patent applications, 
inquiries, comments and other materials relating to the contemplated 
exclusive license should be directed to: Elaine White, M.B.A., 
Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD. 20852-3804; Telephone: (301) 496-7056, x282; Facsimile 
(301) 402-0220; E-mail [email protected].

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be 
royalty-bearing and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be 
granted unless within sixty (60) days from the date of this published 
notice, the NIH receives written evidence and argument that establish 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: August 3, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-20194 Filed 8-10-01; 8:45 am]
BILLING CODE 4140-01-P